{"id":71780,"date":"2026-08-06T00:35:24","date_gmt":"2026-08-05T16:35:24","guid":{"rendered":"https:\/\/flcube.com\/?p=71780"},"modified":"2026-08-06T00:35:25","modified_gmt":"2026-08-05T16:35:25","slug":"pfizer-reports-q2-2026-revenue-of-15-0b-raises-full-year-guidance-as-launched-and-acquired-products-surge-18","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71780","title":{"rendered":"Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) reported financial results for the second quarter of 2026, with <strong>revenues of USD 15.0 billion<\/strong>, representing <strong>1% year-over-year operational growth<\/strong>. <strong>Launched and Acquired Products grew 18%<\/strong>, while revenues excluding <strong>Comirnaty and Paxlovid increased 5% operationally<\/strong>. The company <strong>raised its full-year 2026 revenue guidance by USD 500 million<\/strong> at the midpoint to a range of <strong>USD 60.5 to USD 62.5 billion<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-financial-performance-snapshot\" class=\"wp-block-heading\">Financial Performance Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q2 2026<\/th><th>YoY Change (Operational)<\/th><th>Full-Year 2026 Guidance<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>USD 15.0B<\/td><td>+1%<\/td><td>USD 60.5\u201362.5B (+$500M midpoint increase)<\/td><\/tr><tr><td><strong>Global Biopharmaceuticals<\/strong><\/td><td>USD 14.661B<\/td><td>+1%<\/td><td>Not disclosed<\/td><\/tr><tr><td><strong>Launched &amp; Acquired Products<\/strong><\/td><td>Not disclosed<\/td><td>+18%<\/td><td>Key growth driver<\/td><\/tr><tr><td><strong>Ex-Comirnaty\/Paxlovid Revenue<\/strong><\/td><td>Not disclosed<\/td><td>+5%<\/td><td>Core business momentum<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-growth-portfolio-performance\" class=\"wp-block-heading\">Growth Portfolio Performance<\/h2>\n\n\n\n<h3 id=\"h-cardiovascular-leadership\" class=\"wp-block-heading\">Cardiovascular Leadership<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Eliquis<\/strong> (apixaban): USD 2,425M (+19% YoY)<\/li>\n\n\n\n<li><strong>Primary driver<\/strong>: Higher net price in U.S. due to pricing dynamics<\/li>\n\n\n\n<li><strong>Partnership<\/strong>: Co-commercialized with Bristol Myers Squibb<\/li>\n\n\n\n<li><strong>Indication<\/strong>: Anticoagulation therapy<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-oncology-expansion\" class=\"wp-block-heading\">Oncology Expansion<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Padcev<\/strong> (enfortumab vedotin): USD 667M (+23% YoY)<\/li>\n\n\n\n<li><strong>Primary drivers<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Increased market share in first-line locally advanced\/metastatic urothelial cancer (la\/mUC)<\/li>\n\n\n\n<li>Launch uptake in cisplatin-ineligible muscle-invasive bladder cancer indication<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Origin<\/strong>: Seagen-developed antibody-drug conjugate (ADC)<\/li>\n\n\n\n<li><strong>Lorbrena<\/strong> (lorlatinib): USD 354M (+37% YoY)<\/li>\n\n\n\n<li><strong>Primary driver<\/strong>: Increased patient share in first-line ALK-positive metastatic NSCLC (ALK+ mNSCLC)<\/li>\n\n\n\n<li><strong>Indication<\/strong>: Targeted therapy for lung cancer<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-rare-disease-franchise\" class=\"wp-block-heading\">Rare Disease Franchise<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vyndaqel Family<\/strong> (Vyndaqel, Vyndamax, Vynmac): USD 1,762M (+8% operational)<\/li>\n\n\n\n<li><strong>Primary drivers<\/strong>: Strong demand and improved access across international markets<\/li>\n\n\n\n<li><strong>Indication<\/strong>: Transthyretin amyloid cardiomyopathy (ATTR-CM)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-business-dynamics\" class=\"wp-block-heading\">Strategic Business Dynamics<\/h2>\n\n\n\n<h3 id=\"h-portfolio-transition-success\" class=\"wp-block-heading\">Portfolio Transition Success<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>COVID-19 Impact<\/strong>: Decline in Comirnaty and Paxlovid revenues partially offset by strong growth in core portfolio<\/li>\n\n\n\n<li><strong>Acquisition Integration<\/strong>: Launched and Acquired Products delivering 18% growth demonstrates successful integration strategy<\/li>\n\n\n\n<li><strong>Diversification Benefit<\/strong>: Balanced exposure across cardiovascular, oncology, and rare disease therapeutic areas<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-commercial-excellence\" class=\"wp-block-heading\">Commercial Excellence<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing Power<\/strong>: Eliquis demonstrating strong pricing dynamics in U.S. market<\/li>\n\n\n\n<li><strong>Market Share Gains<\/strong>: Padcev and Lorbrena showing significant competitive positioning improvements<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong>: Vyndaqel family benefiting from international market access improvements<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-guidance-amp-strategic-outlook\" class=\"wp-block-heading\">Forward Guidance &amp; Strategic Outlook<\/h2>\n\n\n\n<h3 id=\"h-revised-full-year-expectations\" class=\"wp-block-heading\">Revised Full-Year Expectations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Guidance<\/strong>: Raised by USD 500 million at midpoint to USD 60.5\u201362.5 billion<\/li>\n\n\n\n<li><strong>Confidence Signal<\/strong>: Upward revision reflects strong H1 performance and positive H2 outlook<\/li>\n\n\n\n<li><strong>Core Business Strength<\/strong>: 5% ex-COVID growth validates sustainable business model<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-growth-catalysts\" class=\"wp-block-heading\">Growth Catalysts<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Pipeline<\/strong>: Continued expansion of ADC and targeted therapy portfolios<\/li>\n\n\n\n<li><strong>Cardiovascular Dominance<\/strong>: Eliquis maintaining leadership position with pricing power<\/li>\n\n\n\n<li><strong>Rare Disease Leadership<\/strong>: Vyndaqel franchise demonstrating sustained global demand<\/li>\n\n\n\n<li><strong>Integration Benefits<\/strong>: Full-year contribution from recent acquisitions expected to accelerate<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-market-positioning\" class=\"wp-block-heading\">Market Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Resilience<\/strong>: Successful navigation of COVID-19 revenue decline through diversified growth drivers<\/li>\n\n\n\n<li><strong>Innovation Focus<\/strong>: Strategic emphasis on high-value therapeutic areas with premium pricing potential<\/li>\n\n\n\n<li><strong>Global Reach<\/strong>: International market expansion providing additional growth vectors beyond U.S. dominance<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, market dynamics, and strategic initiatives. Actual results may differ due to risks including competitive pressures, regulatory changes, market access challenges, and economic conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Q2-2026-PFE-Earnings-Release-FINAL.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Q2-2026-PFE-Earnings-Release-FINAL.\"><\/object><a id=\"wp-block-file--media-b56473e0-46f2-41cf-83dd-01a20f5cf99c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Q2-2026-PFE-Earnings-Release-FINAL.pdf\">Q2-2026-PFE-Earnings-Release-FINAL<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Q2-2026-PFE-Earnings-Release-FINAL.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b56473e0-46f2-41cf-83dd-01a20f5cf99c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026, with revenues&#8230;<\/p>\n","protected":false},"author":1,"featured_media":71782,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27,863,309],"class_list":["post-71780","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-nyse-pfe","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18% - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026, with revenues of USD 15.0 billion, representing 1% year-over-year operational growth. Launched and Acquired Products grew 18%, while revenues excluding Comirnaty and Paxlovid increased 5% operationally. The company raised its full-year 2026 revenue guidance by USD 500 million at the midpoint to a range of USD 60.5 to USD 62.5 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71780\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026, with revenues of USD 15.0 billion, representing 1% year-over-year operational growth. Launched and Acquired Products grew 18%, while revenues excluding Comirnaty and Paxlovid increased 5% operationally. The company raised its full-year 2026 revenue guidance by USD 500 million at the midpoint to a range of USD 60.5 to USD 62.5 billion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71780\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T16:35:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-05T16:35:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0509.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71780#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71780\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%\",\"datePublished\":\"2026-08-05T16:35:24+00:00\",\"dateModified\":\"2026-08-05T16:35:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71780\"},\"wordCount\":468,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71780#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0509.webp\",\"keywords\":[\"Finanical Reports\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71780#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71780\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71780\",\"name\":\"Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18% - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71780#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71780#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0509.webp\",\"datePublished\":\"2026-08-05T16:35:24+00:00\",\"dateModified\":\"2026-08-05T16:35:25+00:00\",\"description\":\"Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026, with revenues of USD 15.0 billion, representing 1% year-over-year operational growth. Launched and Acquired Products grew 18%, while revenues excluding Comirnaty and Paxlovid increased 5% operationally. The company raised its full-year 2026 revenue guidance by USD 500 million at the midpoint to a range of USD 60.5 to USD 62.5 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71780#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71780\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71780#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0509.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0509.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71780#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18% - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026, with revenues of USD 15.0 billion, representing 1% year-over-year operational growth. Launched and Acquired Products grew 18%, while revenues excluding Comirnaty and Paxlovid increased 5% operationally. The company raised its full-year 2026 revenue guidance by USD 500 million at the midpoint to a range of USD 60.5 to USD 62.5 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71780","og_locale":"en_US","og_type":"article","og_title":"Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%","og_description":"Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026, with revenues of USD 15.0 billion, representing 1% year-over-year operational growth. Launched and Acquired Products grew 18%, while revenues excluding Comirnaty and Paxlovid increased 5% operationally. The company raised its full-year 2026 revenue guidance by USD 500 million at the midpoint to a range of USD 60.5 to USD 62.5 billion.","og_url":"https:\/\/flcube.com\/?p=71780","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-05T16:35:24+00:00","article_modified_time":"2026-08-05T16:35:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0509.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71780#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71780"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%","datePublished":"2026-08-05T16:35:24+00:00","dateModified":"2026-08-05T16:35:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71780"},"wordCount":468,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=71780#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0509.webp","keywords":["Finanical Reports","NYSE: PFE","Pfizer"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71780#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71780","url":"https:\/\/flcube.com\/?p=71780","name":"Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18% - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=71780#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=71780#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0509.webp","datePublished":"2026-08-05T16:35:24+00:00","dateModified":"2026-08-05T16:35:25+00:00","description":"Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026, with revenues of USD 15.0 billion, representing 1% year-over-year operational growth. Launched and Acquired Products grew 18%, while revenues excluding Comirnaty and Paxlovid increased 5% operationally. The company raised its full-year 2026 revenue guidance by USD 500 million at the midpoint to a range of USD 60.5 to USD 62.5 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71780#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71780"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=71780#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0509.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0509.webp","width":1080,"height":608,"caption":"Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71780#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0509.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71780"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71780\/revisions"}],"predecessor-version":[{"id":71783,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71780\/revisions\/71783"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/71782"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}